CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Primary central nervous system lymphoma (PCNSL) is known as one of the incurable brain tumors. In March 2020, Tirabrutinib (TIR), a second-generation oral Bruton’s tyrosine kinase inhibitor, was approved for the indication of relapsed or refractory PCNSL (rrPCNSL) based on the results of a phase I/I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mishima, Kazuhiko, Narita, Yoshitaka, Nagane, Motoo, Terui, Yasuhito, Arakawa, Yoshiki, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Aoi, Arata, Nishikawa, Ryo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650894/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados